Measures of cell turnover (proliferation and apoptosis) and their association with survival in breast cancer

Clinical Cancer Research

Volumn 7, Issue 6, 2001, Pages 1716-1723

  Liu, Shuqing ^a   Edgerton, Susan M ^a   Moore, Dan H ^b   Thor, Ann D ^c  

^a EVANSTON NORTHWESTERN HEALTHCARE   (United States)

^b CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MONOCLONAL ANTIBODY KI 67; ONCOPROTEIN; PROTEIN P53; UNCLASSIFIED DRUG;

ADULT; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER SIZE; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MITOSIS; NICK END LABELING; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; APOPTOSIS; BREAST NEOPLASMS; CELL DIVISION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IN SITU NICK-END LABELING; MIDDLE AGED; MITOSIS; MULTIVARIATE ANALYSIS; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; TIME FACTORS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034896073     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Mechanisms and genes of cellular suicide
2. p53: Prospects for cancer gene therapy
3. Regulatory imbalances in cell proliferation and cell death during oncogenesis in transgenic mice
4. Cell division versus cell death: A functional model of multistep neoplasia
5. Counting of apoptotic cells: A methodological study in invasive breast cancer
6. Counting apoptosis- Why and how?
7. Apoptosis
8. Apoptosis occurs more frequently in metastatic foci than in primary lesions of human colorectal carcinomas: Analysis by terminal-deoxynucleotidyl-transferase-mediated dUTP-biotin nick end labeling
9. Apoptosis as a prognostic factor in colorectal carcinoma
10. Association between the apoptotic index and established prognostic parameters in endometrial adenocarcinoma
11. Frequency of apoptotic bodies positively correlates with Gleason grade in prostate cancer
12. Proliferation, apoptosis, and cell cycle regulation in prostatic carcinogenesis
13. Apoptosis in breast cancer as related to histopathological characteristics and prognosis
14. Apoptosis in breast carcinomas detected with monoclonal antibody to single-stranded DNA: Relation to bcl-2 expression, hormone receptors, and lymph node metastases
15. Apoptotic index correlates to bcl-2 and p53 protein expression, histological grade, and prognosis in invasive breast cancers
16. Apoptosis during breast carcinoma progression
17. Cell cycle control and cancer
18. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21
19. Cell surface trafficking of Fas: A rapid mechanism of p53-mediated apoptosis
20. Accumulation of p53 tumor suppresser gene protein: An independent marker of prognosis in breast cancers
21. Bcl-2 and p53 expression in node-negative breast carcinoma: A study with long-term follow-up
22. Widespread p53 overexpression in human malignant tumors. An immunohistochemical study using methacarn-fixed, embedded tissue
23. Prognostic importance of c-erbB-2 expression in breast cancer
24. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer
25. Prognostic factors in breast cancer: College of American Pathologists Consensus Statement 1999
26. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer
27. Association of c-erbB-2 protein overexpression with high rate of cell proliferation, increased risk of visceral metastasis, and poor long-term survival in breast cancer
28. Down-regulation of HER2/neu expression induces apoptosis in human cancer cells that overexpress HER2/neu
29. Assessment of histologic grade
30. Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics
31. Proliferation markers in turnouts: Interpretation and clinical value
32. Apoptosis, its significance in cancer and cancer therapy
33. Reproducibility of mitosis counting in 2, 469 breast cancer specimens: Results from the multicenter morphometric mammary carcinoma project
34. Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): A study of incidence and correlation with outcome in breast cancer
35. The association of p53 immunopositivity with tumor proliferation and other prognostic indicators in breast cancer
36. The HER2 (c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast
37. Regression models and life-tables with discussion
38. The biology of cell death in tumours
39. Apoptosis occurs more frequently in intraductal carcinoma than in infiltrating duct carcinoma of human breast cancer and correlates with altered p53 expression: Detected by terminal-deoxynucleotidyl-transferase-mediated dUTP-FITC nick end labeling (TUNEL)
40. Oncogenes and cell death
41. The clinical relevance and assessment of apoptotic cell death
42. A matter of life and cell death
43. Usefulness of immunohistochemical staining for p53 in the prognosis of breast carcinomas: Correlations with established prognosis parameters and with the proliferation marker, MIB-1
44. Neu differentiation factor induces ErbB2 down-regulation and apoptosis of ErbB2-overexpressing breast tumor cells
45. What is an apoptotic index measuring? A commentary
46. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation
47. False positive staining in the TUNEL assay to detect apoptosis in liver and intestine is caused by endogenous nucleases and inhibited by diethyl pyrocarbonate
48. TUNEL apoptotic cell detection in tissue sections: Critical evaluation and improvement